Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Haemonetics Provides Update On Hemerus Medical Acquisition - Quick Facts

RELATED NEWS
Trade HAE now with 
9/17/2012 7:17 PM ET

Haemonetics Corp. (HAE: Quote) issued an update on the status of its previously announced agreement to acquire Hemerus Medical, LLC , a Minnesota-based company that develops innovative technologies for the collection of whole blood and for the processing and storage of blood components. Hemerus' US New Drug Application and EU Medical Device Directive technical file for the SOLX whole blood collection system had been submitted to the FDA and TUV SUD notified body, respectively.

The company announced that it has learned that Hemerus has received a request from the FDA for resubmission of their application with additional information. As a result, the timing of the closing of the acquisition, which is contingent upon receipt of FDA approval, is still pending and now is expected to occur early in fiscal 2014.

In addition, the company said it has also learned that Hemerus has received CE Marking (Conformite Europeenne) in the European Union to market SOLX with the world's first 56-day red blood cell storage indication.

Haemonetics said it plans include delivery of its first whole blood automation software package, an automated whole blood collection device and continued development of acquired Pall whole blood products. We believe SOLX remains an important part of the strategy for rapid market adoption of the whole blood product suite.

The FDA request for resubmission has minimal effect on our pipeline development since the inclusion of the SOLX solution in these products was contemplated for fiscal 2014 and beyond.

Haemonetics noted that it paid $1 million cash in its first fiscal 2013 quarter and, upon receipt of the aforementioned FDA approvals for the product, will pay the remainder of the $27 million purchase price for Hemerus Medical. Additionally, Haemonetics has agreed to pay a royalty of up to $14 million on future sales of SOLX-based products.

Register
To receive FREE breaking news email alerts for Haemonetics Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Hewlett-Packard Co. said Wednesday after the markets closed that its second quarter profit fell 32% from last year, hurt by lower revenue and weaker margins amid a slump in PC sales. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Stocks showed a substantial downturn over the course of the trading day on Wednesday after seeing some strength in morning trading. Renewed worries about the Federal Reserve tapering its asset purchase program contributed to the sharp pullback by the markets. The major averages climbed off their worst levels going into the close but still ended the day firmly negative. Some members of the Federal Reserve favor scaling back the central bank's $85 billion a month asset purchase program this summer as long as the economy continues to improve, according the the minutes of the Fed's April 30-May 1 meeting. "A number of participants expressed willingness to adjust the...
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.